Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis

Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis

George Dranitsaris,1 Lesley G Shane,2 Mark Crowther,3 Guillaume Feugere,4 Seth Woodruff2 1Health Economic and Outcomes Research, Augmentium Pharma Consulting Inc, Toronto, ON, Canada; 2Pfizer Inc, New York, NY, USA; 3McMaster University, Hamilton, ON, 4Pfizer Canada, Montreal, QC, Canada Background:...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Dranitsaris G, Shane LG, Crowther M, Feugere G, Woodruff S
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Dove Medical Press 2017-01-01
Sarja:ClinicoEconomics and Outcomes Research
Aiheet:
Venous thromboembolism
cancer
recurrence
low molecular weight heparin
dalteparin
vitamin K antagonists
Linkit:https://www.dovepress.com/dalteparin-versus-vitamin-k-antagonists-for-the-prevention-of-recurren-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/dalteparin-versus-vitamin-k-antagonists-for-the-prevention-of-recurren-peer-reviewed-article-CEOR

Samankaltaisia teoksia